These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30968258)

  • 1. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis.
    Hartman SJF; Boeddha NP; Ekinci E; Koch BCP; Donders R; Hazelzet JA; Driessen GJ; de Wildt SN
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1255-1260. PubMed ID: 30968258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
    Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
    Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
    Chosidow A; Benaboud S; Beranger A; Zheng Y; Moulin F; Dupic L; Renolleau S; Treluyer JM; Oualha M
    Therapie; 2020; 75(6):633-640. PubMed ID: 32593420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock.
    Bjerre A; Brusletto B; Høiby EA; Kierulf P; Brandtzaeg P
    Crit Care Med; 2004 Feb; 32(2):433-8. PubMed ID: 14758160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
    Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
    Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.
    Hartman SJF; Brüggemann RJ; Orriëns L; Dia N; Schreuder MF; de Wildt SN
    Clin Pharmacokinet; 2020 Feb; 59(2):173-205. PubMed ID: 31432468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Paediatr Drugs; 2006; 8(2):131-8. PubMed ID: 16608373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.
    Maksoud E; Koehl B; Facchin A; Ha P; Zhao W; Kaguelidou F; Benkerrou M; Mariani P; Faye A; Lorrot M; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic parameters over time during sepsis and the association of target attainment and outcomes in critically ill children and young adults receiving ceftriaxone.
    Tang Girdwood S; Tang P; Fenchel M; Dong M; Stoneman E; Jones R; Ostermeier A; Curry C; Forton M; Hail T; Mullaney R; Diseroad E; Punt N; Kaplan J; Vinks AA
    Pharmacotherapy; 2023 Jul; 43(7):609-621. PubMed ID: 36727212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.
    Roggeveen LF; Fleuren LM; Guo T; Thoral P; de Grooth HJ; Swart EL; Klausch TLT; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers PWG
    Trials; 2019 Dec; 20(1):745. PubMed ID: 31852491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?
    De Cock PA; Desmet S; De Jaeger A; Biarent D; Dhont E; Herck I; Vens D; Colman S; Stove V; Commeyne S; Vande Walle J; De Paepe P
    J Antimicrob Chemother; 2017 Mar; 72(3):801-804. PubMed ID: 27999035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical aspects and outcome of meningococcal disease due to Neisseria meningitidis of serogroup W135 in 5 children].
    Faye A; Mariani-Kurkjian P; Taha MK; Louzeau C; Bingen E; Bourrillon A
    Arch Pediatr; 2005 Mar; 12(3):291-4. PubMed ID: 15734127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children.
    Hartman SJF; Upadhyay PJ; Mathôt RAA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
    J Antimicrob Chemother; 2022 May; 77(6):1725-1732. PubMed ID: 35383374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations.
    Aardema H; Bult W; van Hateren K; Dieperink W; Touw DJ; Alffenaar JC; Zijlstra JG
    J Antimicrob Chemother; 2020 Feb; 75(2):441-448. PubMed ID: 31697336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neisseria meningitidis strains with decreased susceptibility to penicillin.
    Van Esso D; Fontanals D; Uriz S; Morera MA; Juncosa T; Latorre C; Duran M
    Pediatr Infect Dis J; 1987 May; 6(5):438-9. PubMed ID: 3110727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.